Primary cutaneous Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma, not otherwise specified, in a nonimmunocompromised young man: A case report

Abstract

Primary cutaneous EBV (Epstein‐Barr virus)‐positive diffuse large B‐cell lymphoma, not otherwise specified (DLBCL, NOS), is an extremely rare disease. The clinical and pathological features of DLBCL, NOS have not been clearly illustrated. We report a case of primary cutaneous EBV‐positive DLBCL, NOS in a 35‐year‐old Chinese male with multiple ulcerated and nodular lesions on his trunk and arms for 6 months. No other organs, except the skin, were involved. The lesions were localized in the dermis with focal necrosis. The tumor cells were immunoblastic‐ or centroblastic‐like cells and diffusely distributed. There were numerous inflammatory cells in the background. The tumor cells were positive for CD20, PAX‐5, MUM1, LMP1, CD30, and Epstein‐Barr virus encodedsmall RNA, but negative for EBNA2. Polymerase chain reaction showed a monoclonal IG gene rearrangement. The patient received 6 cycles of CHOP (cyclophosphamide, hydroxydaunorubicin, Oncovin®, prednisone) chemotherapy and went into complete remission. There was no evidence of relapse after 35 months of follow‐up.

Primary cutaneous diffuse large B-cell lymphoma after total knee arthroplasty: a case study and a systematic review of its cutaneous manifestations and treatment options

“…Chronic inflammation is a precursor of most tumours, and Epstein Barr virus infection is often implicated in primary cutaneous diffuse large B-cell lymphoma, which is concerned with chronic inflammatory stimulation [ 52 , 53 ]. Pro-inflammatory mediator not only participates in acute infectious diseases but is also involved in the evolution of sterile inflammation [ 54 ].…”

Tumor Lysis Syndrome: Introduction of a Cutaneous Variant and a New Classification System

“…The key feature is necrosis and ulceration of the skin tumors in the absence of therapy. In addition, albeit rare to date, cases suggestive of this diagnosis have been observed in patients with untreated solid tumors (such as melanoma, breast cancer, and Kaposi sarcoma) [7,[27][28][29][30][31][32][33][34][35][36][37][38][39].…”

“…There is subsequent necrosis and ulcer formation as the clinical presentation of spontaneous (idiopathic) cutaneous tumor lysis syndrome. However, it remains unclear if some of these cases were accompanied by rapid tumor death, a key feature of cutaneous tumor lysis syndrome [7,[27][28][29][30][31][32][33][34][35][36][37][38][39]. Solid tumors: In addition to patients with Kaposi sarcoma, characteristics possibly compatible with solid tumor-associated spontaneous (idiopathic) cutaneous tumor lysis syndrome have also been reported in patients with other solid tumors (Table 4) [7,[35][36][37][38][39].…”

“…[27][28][29][30]. The B-cell neoplasms of patients possibly presenting with characteristics of spontaneous (idiopathic) cutaneous tumor lysis syndrome include cutaneous B-cell lymphoma, intravascular B-cell lymphoma, primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified, and cutaneous lymphomatoid granulomatosis (Table 3)[31][32][33][34]. of 50 patients with primary and recurrent mycosis fungoides, 14 had either erythroderma and/or ulcerated lesions, on initial presentation; some of the patients with ulcerated lesions might be…”